Cardiff Oncology

Turning the Tide on Cancer

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers.

Our lead asset is onvansertib, a PLK1 inhibitor that we are evaluating in combination with standard of care (SoC) therapeutics in clinical programs targeting indications with the greatest need for new treatment options.

These programs and our broader development strategy are designed to target tumor vulnerabilities to overcome treatment resistance and deliver superior clinical benefit to patients compared to the SoC.

CORPORATE PRESENTATION

Targeting PLK1 opens doors to large patient populations

5 3 RET ROS1 Annual eligible US patients (’000s)* ONVANSERTIB 15 SCLC TNBC 12 mPDAC 39 23 mCRC Targets with oncogenic alterations ROS1RETKRAS G12CEGFRTRK Targets without oncogenic alterations PLK1PARPCDK4/6PD1/PDL1VEGF *ROS1 estimated eligible patients presented in Turning Point Therapeutics’ corporate presentation May 2022 slide 6 (NSCLC disease incidence in the US of 140k of which 2% of patients harbor ROS1 translocation). RET estimated eligible patients presented in Loxo Oncology’s corporate presentation January 2018 disclosed on Form 8-K (Jan 8, 2018). mCRC estimated population includes 2nd line, KRAS- and NRAS-mutated cancers. mPDAC estimated population includes 2nd line PDAC patients. TNBC estimated population includes invasive, 2nd line TNBC patients. SCLC estimated population includes SCLC salvage patients. 2L K/N-mut 2L 2L invasive Salvage 30 20 10 0 40

Current Clinical Programs

KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

Phase 1b/2 open-label single arm trial (NCT03829410)

Combining onvansertib with FOLFIRI/bevacizumab to improve objective response rate (ORR) and progression-free survival (PFS)

LEARN MORE

KRAS/NRAS-Mutated Metastatic Colorectal Cancer (mCRC)

ONSEMBLE Phase 2 open-label randomized trial (NCT05593328)

Combining onvansertib with FOLFIRI/bevacizumab vs FOLFIRI/bevacizumab to demonstrate the contribution of onvansertib to improve objective response rate (ORR) and progression-free survival (PFS)

LEARN MORE

Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Phase 2 open-label trial
(NCT04752696)

Combining onvansertib with nanoliposomal irinotecan and 5-FU to improve objective response rate (ORR) and progression-free survival (PFS)

LEARN MORE